CURE’s liver cancer page features the latest cancer news and updates on liver cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in liver cancer.
June 24th 2022
Treatment with an experimental drug delivered through a minimally invasive procedure may show promise in patients with liver cancer that cannot be treated with surgery.
June 3rd 2022
Although she has always been driven to excel, Karen Driskill's, M.S., RN, purpose became more focused after her mother-in-law passed away from intrahepatic cholangiocarcinoma in 2010.
May 6th 2022
The priority review means that the FDA plans to speed up its review of Imfinzi combined with chemotherapy in patients with advanced or metastatic biliary tract cancer.
April 8th 2022
From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.
April 5th 2022
“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.
March 31st 2022
The FDA plans to decide on whether to approve futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors a certain genetic mutation by September.
March 25th 2022
From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.
March 15th 2022
The combination of Cabometyx and Tecentriq failed to improve overall survival in patients with advanced hepatocellular carcinoma, the most common type of primary liver cancer, compared with single-agent Tecentriq or Nexavar.
March 8th 2022
Despite several FDA drug approvals over the past few years in the cholangiocarcinoma space, many patients are ineligible for these treatments as a first option, signaling a significant unmet need.
February 7th 2022
Treatment with a combination of PD-1 inhibition, minimally invasive chemotherapy and Lenvima improved outcomes for patients with unresectable liver cancer compared to PD-1 inhibition and Lenvima alone.
February 3rd 2022
A woman whose husband died from cancer explains how she shattered a piece of pottery and glued it back together, to represent the cracks of her life left by her loss and how her husband remains connected to her.
January 27th 2022
An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.
January 26th 2022
Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.
January 24th 2022
The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.
January 23rd 2022
Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.
January 22nd 2022
Treating patients with liver cancer initially with Lenvima instead of the standard of care was associated with a survival benefit, according to recent research.
January 21st 2022
The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.
December 28th 2021
The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.
December 22nd 2021
CURE® took a look back at our most-read liver cancer stories from this year.
November 8th 2021
External-beam radiation, a noninvasive option for bridging therapy, may be underused compared with other liver-directed therapies and may highlight a treatment gap in this area.
November 5th 2021
Cholangiocarcinoma Foundation volunteer Lourdes Rocha leads the Veterans Program and shares her experience filing claims with the VA in a recorded webinar.
November 4th 2021
Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.
October 15th 2021
Data from a phase 3 trial show that frontline tremelimumab plus Imfinzi improved overall survival in patients with liver cancer.
October 15th 2021
The results, according to one of the study’s authors, indicate that liver cancer is an underrecognized and deadly cancer that is increasingly affecting people living in rural areas of the United States.
September 29th 2021
The new approach of chemotherapy plus Opdivo offers “the best of both treatment approaches,” says one expert.
September 24th 2021
Results from the study highlight the need to organize better screening and treatment plans for patients with liver cancer coinfected with hepatitis B, hepatitis C or HIV.
September 3rd 2021
The FDA approval of Tibsovo marks the first targeted therapy for patients with this liver cancer subtype.
August 25th 2021
Tibsovo — which is the first targeted therapy approved for this patient population — improved survival in patients with a subtype of liver cancer.
August 5th 2021
The results, according to the study authors, demonstrate a need to better inform older patients during treatment about survivorship after liver cancer.